491 related articles for article (PubMed ID: 18784151)
1. Pulmonary function tests.
Behr J; Furst DE
Rheumatology (Oxford); 2008 Oct; 47 Suppl 5():v65-7. PubMed ID: 18784151
[TBL] [Abstract][Full Text] [Related]
2. Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma.
Garin MC; Highland KB; Silver RM; Strange C
J Rheumatol; 2009 Feb; 36(2):330-6. PubMed ID: 19208563
[TBL] [Abstract][Full Text] [Related]
3. Esophageal involvement and pulmonary manifestations in systemic sclerosis.
Marie I; Dominique S; Levesque H; Ducrotté P; Denis P; Hellot MF; Courtois H
Arthritis Rheum; 2001 Aug; 45(4):346-54. PubMed ID: 11501722
[TBL] [Abstract][Full Text] [Related]
4. Validity of the Saint George's Respiratory Questionnaire in the evaluation of the health-related quality of life in patients with interstitial lung disease secondary to systemic sclerosis.
Beretta L; Santaniello A; Lemos A; Masciocchi M; Scorza R
Rheumatology (Oxford); 2007 Feb; 46(2):296-301. PubMed ID: 16877463
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic options for systemic sclerosis related interstitial lung diseases.
Mouthon L; Bérezné A; Guillevin L; Valeyre D
Respir Med; 2010 Jul; 104 Suppl 1():S59-69. PubMed ID: 20630349
[TBL] [Abstract][Full Text] [Related]
6. Parenchymal and vascular interactions in the pathogenesis of nonspecific interstitial pneumonia in systemic sclerosis and idiopathic interstitial pneumonia.
Franco de Carvalho E; Parra ER; de Souza R; Muxfeldt A'b Saber A; Capelozzi VL
Respiration; 2008; 76(2):146-53. PubMed ID: 18073456
[TBL] [Abstract][Full Text] [Related]
7. Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease.
Le Gouellec N; Duhamel A; Perez T; Hachulla AL; Sobanski V; Faivre JB; Morell-Dubois S; Lambert M; Hatron PY; Hachulla E; Béhal H; Matran R; Launay D; Remy-Jardin M
PLoS One; 2017; 12(8):e0181692. PubMed ID: 28763468
[TBL] [Abstract][Full Text] [Related]
8. Interstitial lung disease in systemic sclerosis.
Bussone G; Mouthon L
Autoimmun Rev; 2011 Mar; 10(5):248-55. PubMed ID: 20863911
[TBL] [Abstract][Full Text] [Related]
9. Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment.
Proudman SM; Stevens WM; Sahhar J; Celermajer D
Intern Med J; 2007 Jul; 37(7):485-94. PubMed ID: 17547726
[TBL] [Abstract][Full Text] [Related]
10. Interstitial lung disease associated with systemic sclerosis: what is the evidence for efficacy of cyclophosphamide?
Bérezné A; Valeyre D; Ranque B; Guillevin L; Mouthon L
Ann N Y Acad Sci; 2007 Sep; 1110():271-84. PubMed ID: 17911442
[TBL] [Abstract][Full Text] [Related]
11. Arterial and interstitial remodelling processes in non-specific interstitial pneumonia: systemic sclerosis versus idiopathic.
de Carvalho EF; Parra ER; de Souza R; A'b Saber AM; Machado Jde C; Capelozzi VL
Histopathology; 2008 Aug; 53(2):195-204. PubMed ID: 18752502
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of treatment for systemic sclerosis interstitial lung disease: results from a meta-analysis.
Broad K; Pope JE
Med Sci Monit; 2010 Sep; 16(9):RA187-90. PubMed ID: 20802426
[TBL] [Abstract][Full Text] [Related]
13. Effect of Bosentan on systemic sclerosis-associated interstitial lung disease ineligible for cyclophosphamide therapy: a prospective open-label study.
Furuya Y; Kuwana M
J Rheumatol; 2011 Oct; 38(10):2186-92. PubMed ID: 21885489
[TBL] [Abstract][Full Text] [Related]
14. Serum level of KL-6 as a marker of interstitial lung disease in patients with juvenile systemic sclerosis.
Veselý R; Vargová V; Ravelli A; Massa M; Oleksák E; D'Alterio R; Martini A; De Benedetti F
J Rheumatol; 2004 Apr; 31(4):795-800. PubMed ID: 15088311
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease.
Launay D; Mouthon L; Hachulla E; Pagnoux C; de Groote P; Remy-Jardin M; Matran R; Lambert M; Queyrel V; Morell-Dubois S; Guillevin L; Hatron PY
J Rheumatol; 2007 May; 34(5):1005-11. PubMed ID: 17444586
[TBL] [Abstract][Full Text] [Related]
16. Reduced exercise capacity in systemic sclerosis patients without pulmonary involvement.
de Oliveira NC; dos Santos Sabbag LM; Ueno LM; de Souza RB; Borges CL; de Sá Pinto AL; Lima FR
Scand J Rheumatol; 2007; 36(6):458-61. PubMed ID: 18092268
[TBL] [Abstract][Full Text] [Related]
17. Interstitial lung disease increases mortality in systemic sclerosis patients with pulmonary arterial hypertension without affecting hemodynamics and exercise capacity.
Michelfelder M; Becker M; Riedlinger A; Siegert E; Drömann D; Yu X; Petersen F; Riemekasten G
Clin Rheumatol; 2017 Feb; 36(2):381-390. PubMed ID: 28028682
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-17 and interleukin-23: importance in the pathogenesis of lung impairment in patients with systemic sclerosis.
Olewicz-Gawlik A; Danczak-Pazdrowska A; Kuznar-Kaminska B; Gornowicz-Porowska J; Katulska K; Trzybulska D; Batura-Gabryel H; Silny W; Poplawski D; Hrycaj P
Int J Rheum Dis; 2014 Jul; 17(6):664-70. PubMed ID: 24467649
[TBL] [Abstract][Full Text] [Related]
19. Determinants of impairment in lung diffusing capacity in patients with systemic sclerosis.
Guarnieri G; Zanatta E; Mason P; Scarpa MC; Pigatto E; Maestrelli P; Cozzi F
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S80-6. PubMed ID: 25897784
[TBL] [Abstract][Full Text] [Related]
20. [Use of pulmonary function tests and biomarkers studies to diagnose and follow-up interstitial lung disease in systemic sclerosis].
Hua-Huy T; Rivière S; Tiev KP; Dinh-Xuan AT
Rev Pneumol Clin; 2014 Dec; 70(6):335-42. PubMed ID: 25457218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
